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1596A ‘‘No-wash’’ Albumin-Dextran Dilution Strategy
for Cord Blood Unit Thaw: High Rate of Engraftment
and a Low Incidence of Serious Infusion Reactions
Juliet N. Barker,1 Michelle Abboud,2 Robert D. Rice,2 Rebecca Hawke,1 Allison Schaible,3
Glenn Heller,4 Vincent La Russa,3 Andromachi Scaradavou5Preparation of cord blood (CB) units for infusion by albumin-dextran dilution without centrifugation may be
advantageous for adult patients to minimize cell loss and, unlike a bedside thaw, is still conducted in the con-
trolled laboratory environment. Therefore, we studied CB transplantation (CBT) using this technique in 54
consecutive CBT recipients .20 kg. Patients (median age542 years [range: 7-66 years]; median weight5
71 kg [range: 24-109]) were transplanted for high-risk hematologic malignancies with myeloablative
(n535) or nonmyeloablative (n519) conditioning and 4-6/6 human leukocyte antigen (HLA)-matched dou-
ble-unit grafts. One hundred seven units were thawed with dilution, whereas 1 red blood cell (RBC)-replete
unit was washed. A 5:1 dextran 40%/25% albumin solution was used. RBC-depleted units (n5104) were di-
luted$5.5-fold (median final volume 200 mL [range: 200-500]), whereas RBC-replete units (n53) were di-
luted$4-fold (median final volume 400 mL [range: 400-535]). Total nucleated cell (TNC) recovery was 86%;
the median infused TNC dose was 2.17107/kg/unit. Although 35 patients (65%) had a total of 45 infusion
reactions (6 nausea, 31 hypertension, 3 pain, 1 rigors/fever, 2 transient hypoxia, 2 renal impairment) requiring
additional therapy, there were no infusion-related serious adverse events, and reactions were not related to
dimethyl sulfoxide (DMSO) dose/kg. Cumulative incidence of sustained donor engraftment was 94% (95%
cumulative incidence [CI]: 87-100) with neutrophil recovery occurring at a median of 25 days (range:
13-43) in myeloablative and 10 days (range: 7-36) in nonmyeloablative recipients. CB thaw with albumin-dex-
tran dilution reduces unit manipulation, and minimizes cell loss, speeds time to infusion, is associated with
a tolerable infusion reaction profile, and a high rate of sustained engraftment in CBT recipients $20 kg.
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Rubinstein et al. [1] originally described the prepa-
ration of cord blood (CB) units for infusion using albu-
min-dextran dilution with centrifugation (‘‘wash’’) to
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6/j.bbmt.2009.08.009viability of the thawed product. This strategy was
initially used for the transplantation of small children,
but has been widely adopted in adult CB transplanta-
tion (CBT) as a matter of convention. Although
DMSO infusion can be associated with infusion
reactions [2], adult and larger pediatric autologous
transplant recipients can tolerate small amounts of
DMSO without clinically significant toxicity. There-
fore, an alternative method to prepare CB for infusion
originally proposed by the St. Louis Cord Blood Bank
[3] is to perform an albumin-dextran dilution without
centrifugation. Such an approach could be advanta-
geous for adults and larger children, as cell loss is min-
imized [4] and time to infusion is shortened, both
desirable for a cryopreserved graft. Finally, unlike
bedside thaw [5], this technique is still conducted in
the controlled environment of the Cytotherapy Labo-
ratory where samples can be immediately taken to
analyze cell recoveries and unit quality. Therefore,
we conducted a prospective study of albumin-dextran
dilution after CB thaw in 54 consecutive recipients of
Table 1. Characteristics of 54 Double Unit CBT Recipients
and Grafts
Sex
Male 30 (56%)
Female 24 (44%)
Biol Blood Marrow Transplant 15:1596-1602, 2009 1597A ‘‘No-wash’’ Albumin-Dextran Dilution Strategy for Cord Blood Unit Thawdouble-unit CBT. Our hypothesis was that preparation
of units for infusion with the ‘‘no-wash’’ technique
would be associated with tolerable infusion reactions
and a high rate of sustained donor engraftment.Age (years)
Median (range) 42 (7-66)
Weight (kg)
Median (range) 71 (24-109)
Diagnosis
Acute leukemia 22
Myelodysplasia 1
Non-Hodgkin lymphoma 20
Hodgkin disease 11
Myeloablative conditioning
Cy 120/ Flu 75/ TBI 1320-1375 18
Mel 140/ Flu 150 7
Cy 50/ Thio 10/ Flu 150/ TBI 400 8
Flu 125/ Thio 10/ TBI 1375 2
Nonmyeloablative conditioning
Cy 50/ Flu 150/ TBI 200 19
Prior autologous transplant 12
HLA-A,-B antigen, -DRB1 allele match to patient
(n5108 units)
6/6 5
5/6 58
4/6 45
Infused TNC107/kg
Median (range) of larger unit (n554) 2.52 (1.42-5.56)
Median (range) of smaller unit (n554) 1.94 (0.92-4.47)
Cy indicates cyclophosphamide; Flu, fludarabine; TBI, total body irradi-
ation; Mel, Melphalan; Thio, Thiotepa; HLA, human leukocyte antigen;
TNC, total nucleated cell.MATERIALS AND METHODS
Patients, Conditioning, and CB Grafts
Recipients of first allograft who were .20 kg were
eligible. Table 1 summarizes characteristics of patients,
preparative regimens, and grafts. Fifty-four consecutive
patients (median age: 42 years [range: 7-66 years],
median weight: 71 kg [range: 24-109]) were transplanted
for high-risk hematologic malignancies with myeloabla-
tive (MA; n535) or nonmyeloablative (NMA; n519)
conditioning according to their age, extent of prior ther-
apy, comorbidities, and diagnosis. All received immune
suppression with cyclosporine A (CsA) and mycopheno-
late mofetil (MMF). CsA was continued until at least day
100 and then tapered in the absence of graft-versus-host
disease (GVHD), whereas MMF was continued until
day 45 and then either stopped or tapered according to
protocol. All patients received posttransplant granulo-
cyte-colony stimulating factor (G-CSF).
Double-unit grafts were used to augment engraft-
ment [6-8]. Units were selected primarily according to
total nucleated cell (TNC) dose, human leukocyte an-
tigen (HLA)-match, and bank of origin, and obtained
from domestic (n578) or international (n530) banks.
The majority (n5104) had undergone at least partial
red blood cell (RBC) depletion prior to cryopreserva-
tion (‘‘RBC depleted’’), whereas 3 were only plasma
depleted (‘‘RBC replete’’). To reduce the amount of
cellular debris infused, only 1 RBC replete unit was
permitted per double-unit graft. Units were 6/6
(n55), 5/6 (n558), and 4/6 (n545) HLA-A, -B anti-
gen, -DRB1 allele matched to the recipient. Patients
were transplanted between February 2006 and
October 2008, and all patients or their guardians
signed informed consent prior to transplantation.Preparation of CB Units for Infusion
All units were stored in LN freezers upon arrival at
2180C. One hundred seven units underwent albu-
min-dextran dilution after thaw, whereas 1 RBC
replete unit was washed prior to inclusion of such units
in the study. Each unit of a double-unit graft was han-
dled separately to avoid potential mixup. Units were
placed in a zip-lock bag, thawed in a 37C waterbath,
and then transferred to a biosafety cabinet. A stock
solution with a 5:1 ratio of 10% dextran 40 (molecular
weight 40,000; Hospira, Lake Forrest, IL) and 25%
human serum albumin (CSL Behring, King of Prusia,
PA) was prepared at room temperature. RBC-depleted
units were diluted at least 5.5-fold, and RBC-repleteunits at least 4 times their original volume with the
standard dilution for units with a cryopreserved vol-
ume of 25 mL being 8-fold (final volume 200 mL).
The required quantity of diluent was calculated and
aliquoted into a 300 or 600 mL transfer pack for units
in a single compartment bag or a cell wash infusion bag
(MedSep double-compartment units). A small volume
of diluent was reserved to rinse bags as needed.
For single-compartment RBC-depleted units the
cryobag was spiked with the single line of tubing and
coupler of the transfer pack. For RBC-replete units
double-spiked transfer sets were used to connect the
bag with the diluent because of their increased viscos-
ity and the risk of tubing blockage. For MedSep units
the double-spiked end of the cell wash infusion bag was
used to spike the large and small compartments, ensur-
ing there were no leaks. For all units an amount of dil-
uent approximately equal to the cryopreserved volume
of the unit was slowly transferred to the cryobag. Once
this initial 1:1 dilution was achieved the tubing was
clamped. Thorough mixing was performed, and the
product was allowed to equilibrate for 1–2 minutes.
It was then drained back into the transfer pack or cell
wash infusion bag. Units frozen in 2 bags were com-
bined before samples were taken.
CB Unit Assessment
A small aliquot was removed from the final cell
mixture for TNC count, ABO blood group, Gram
1598 Biol Blood Marrow Transplant 15:1596-1602, 2009J. N. Barker et al.stain and culture, and assays of unit quality. Unit qual-
ity was evaluated by trypan blue exclusion, flow
cytometric assay of CD341 and CD31 viability using
7-amino-actinomycin D, and colony-forming unit
(CFU) assays. The original cryobag was sent to the
Diagnostic Molecular Pathology Laboratory for
DNA extraction and assessment of donor polymor-
phisms. TNC count per kilogram (kg) was calculated
as: TNC count/mL  the volume of the final product
divided by the patient’s weight. The infused viable
CD341 dose/kg was calculated as: TNCCD341 via-
bility  percentage of CD341 cells of the total sample
divided by the patient’s weight. CFU assays were per-
formed using a total of 1105 cells plated in duplicate
and colony growth was evaluated by light microscopy
at 14 days.Management of CB Infusion and Infusion-
Related Adverse Reactions
All patients received premedication with oral acet-
aminophen and i.v. diphenhydramine (or hydroxy-
zine); most of the patients also received lorazepam.
In addition, patients received high volume hydration
4 to 6 hours pretransplant and 12 to 24 hours post-
transplant. CB units were infused consecutively with
infusion of the first unit starting within 2 hours of
thaw. The median interval between infusion of the first
and second unit was 10 minutes (range: 0–100 min-
utes). Experienced transplant nurses were present dur-
ing infusion of both units and patients were closely
monitored: vital signs were recorded before each unit
infusion, every 15 minutes during infusion, immedi-
ately after each unit, and then every 15 minutes2,
every 30 minutes2, and every 60 minutes4. Emer-
gency medications including i.v. lorazepam and
hydralazine were at the bedside for immediate
administration in the event of nausea, hypertension,
or other reactions.
A serious infusion reaction was defined as any life-
threatening event related to CB infusion such as: ana-
phylaxis; cardiac, pulmonary, or acute renal failure;
seizure; transfer to intensive care unit; or death within
48 hours of CB infusion. Hypoxia was defined as oxy-
gen saturation of\94%. Hypertension was defined as
a systolic pressure of .160 and/or a diastolic pressure
of .90 mmHg, and bradycardia was a heart rate of
\50 beats/min. Renal insufficiency was defined as
a 1.5-fold increase in serum creatinine over the day
zero baseline and greater than the upper limit of
normal for age.
The amount of DMSO per unit was estimated
based on the cryopreservation volume of the unit and
the concentration of DMSO reported by the CB
bank. When no concentration was reported, the bank-
ing standard of 10% DMSO (v/v) in the final volume of
the cryopreserved product was used. The amount ofDMSO infused was calculated as the total amount of
DMSO contained in the 2 units of each patient’s graft,
divided by the patient’s body weight.
Assessment of Donor Engraftment and GVHD
Time to neutrophil recovery was defined as the
first of 3 consecutive days with an absolute neutrophil
count (ANC) .0.5109/L. Time to platelet recovery
was defined as the first of 3 consecutive days at
.50109/L and at least 7 days without platelet trans-
fusion support. Sustained donor engraftment was
defined as sustained donor-derived count recovery
with donor chimerism of at least 90% (both units com-
bined). Donor chimerism was determined serially on
bone marrow and/or peripheral blood at days 21, 28,
60, 100, 180, and 360 after transplantation by quanti-
tative polymerase chain reaction of informative poly-
morphic short tandem repeat (STR) regions of DNA
from each donor units and the recipient using a multi-
plex kit (GenePrint Fluorescent STR Marker Kit,
Promega, Madison, WI) [7]. The engrafting unit con-
tributed .50% of the total donor chimerism in serial
testing. Patients were evaluated weekly for develop-
ment and extent of GVHD. Overall staging of acute
GVHD (aGVHD) was based on IBMTR criteria [9].
Statistical Analysis
The probability of neutrophil and platelet engraft-
ment, aGVHD, and treatment-related mortality
(TRM) were computed using the cumulative incidence
(CI) function. For neutrophil engraftment early death
was the competing risk, whereas death or graft failure
were the competing risks for aGVHD. Relapse was the
competing event for TRM. Overall surival (OS) and
disease-free survival (DFS) were calculated using
Kaplan-Meier methodology.RESULTS
Cell Recoveries
RBC-depleted units (n5104) had a median cryo-
preserved volume of 25 mL (range: 21-65) and were
diluted $5.5-fold (median final volume5200 mL
[range: 200-500]). The RBC-replete units (n53) had
a larger median cryopreserved volume of 90 mL
(range: 89-95) and were diluted $4-fold (median final
volume5400 mL [range: 400-535]). Cell doses and
recoveries are summarized in Table 2.
Infusion Reactions
There were no serious adverse events related
to infusion. Nineteen patients (35%) had no reactions.
Thirty-five patients (65%) had a total of 45 reactions
requiring additional therapy. Six patients had nausea
treated with additional i.v. lorazepam. Thirty-one
Table 2. Postthaw Recoveries of CB Units Thawed with Di-
lution (n5107)*
Median or % (Range)
Prethaw TNC107/kg 2.66 (1.06-6.87)
Postthaw TNC107/kg 2.27 (0.92-5.85)
% TNC recovery 86% (50-121%)
% CD34+ viability 90% (34-98%)
Postthaw CD34+105/kg/unit† 0.90 (0.13-3.69)
Postthaw CFU-GM104/kg/unit 1.25 (0.00-5.79)
TNC indicates total nucleated cell; CB, cord blood; CFU, colony-
forming unit; GM, granulocyte macrophage.
*The single washed unit is excluded.
†The infused dose of viable CD34+ cells.
Figure 1. Distribution of infused DMSO doses/kg with double-unit CB
grafts prepared with albumin dilution and incidence of infusion reactions
in 53 patients. To most accurately represent the DMSO dose with two
unwashed units the single patient who received 1 washed unit is ex-
cluded from this analysis.
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and/or furosemide. Three patients had chest or ab-
dominal pain treated with a small dose of i.v. narcotic,
and 1 had rigors/fever treated with intravenous meper-
idine. Two patients had transient hypoxia treated with
supplemental oxygen by nasal cannula. Two patients
had transient renal insufficiency: 1 recipient of 2
RBC-depleted units had a serum creatinine peak of
1.6 mg/dL, which returned to baseline by day 7 post-
transplant, and 1 recipient of a RBC-depleted and
RBC-replete unit had a serum creatinine peak of 2.7
mg/dL, which returned to baseline by day 22 post-
transplant. These 2 patients were managed by extend-
ing intravenous hydration and other supportive
measures. Finally, 3 patients had transient asymptom-
atic bradycardia not requiring therapy. In 1 patient the
infusion was stopped and the bradycardia spontane-
ously resolved after 19 minutes; the infusion was
then completed uneventfully. In the other 2 patients,
the infusion was continued and the bradycardia re-
solved within 25 and 60 minutes of completion of the
second unit, respectively.
Overall, of the 35 patients with infusion reactions,
31 received RBC-depleted units, 3 received 1 RBC-
depleted and 1 RBC-replete unit, and 1 received
a RBC-depleted and a washed unit. Further, 21
(60%) patients reacted during the first unit, and 14
(40%) reacted during the second unit. Nausea, hyper-
tension, pain, or hypoxia occurred during either the
first or second unit, whereas all 3 episodes of bradycar-
dia occurred during the second unit. There was no
relationship between the timing of administration of
premedications and the occurrence of infusion reac-
tions (data not shown). The mean total dose of
DMSO administered with the 2 units was 0.117 g/kg
(range: 0.05-0.28), and there was no relationship
between the DMSO dose and infusion reactions except
at the highest dose level where all 4 patients had
a reaction (Figure 1).Transplant Outcomes
Three patients (2 recipients of MA and 1 of
NMA conditioning) had graft failure. Thus, the CIof sustained donor engraftment was 94% by day 50
(95% CI: 87-100) with neutrophil recovery to
$0.5109/L occurring at a median of 25 days (range:
13-43) in MA and 10 days (range: 7-36) in NMA CBT
recipients (Figure 2A). The CI of platelet recovery to
.50109/L was 80% at day 180 (95% CI: 68-92)
overall, and occurred at a median of 50 days (range:
35-182) in recipients of MA and 38 days (range: 24-
59) in NMA conditioning (Figure 2B). Of the 51 pa-
tients with sustained donor-derived hematopoiesis,
50 engrafted with a single unit (median infused TNC
2.21107/kg [range: 1.32-5.56] and median infused
CD341 dose 0.90105/kg [range: 0.13-3.69]), whereas
a single patient had sustained engraftment of both
units.
The CI of day 100 grade II-IV aGVHD was 44%
(95% CI: 30-58). Nine patients had grade II, 13 had
grade III, and 1 had grade IV aGVHD. Eleven of 43
(26%) of evaluable patients have either late aGVHD
or chronic GVHD (cGVHD) to date. With a median
follow-up of 11 months, 14 patients have died of trans-
plant-related causes and 10 patients have relapsed.
Thus, the 1 year OS is 65% (95% CI: 51-79) and the
1-year DFS is 56% (95% CI: 42-70) (Figure 3).DISCUSSION
The methodology of preparation of cryopreserved
CB units for infusion was originally described by Ru-
binstein and colleagues in 1995 [1]. Notably, although
the authors recommended thaw with removal of the
cryoprotectant by centrifugation (‘‘wash’’), they em-
phasized that (p. 10119): ‘‘Progenitor cell viability is
measurably decreased when thawed cells, still
Figure 2. Cumulative incidence of sustained neutrophil engraftment
(A) and platelet engraftment (B) after CBTwith double-unit grafts pre-
pared with albumin-dextran dilution. Recipients of ablative and nonmye-
loablative conditioning are shown separately. Although early recovery in
recipients of nonmyeloablative conditioning resulted from transient
autologous recovery, all engrafting patients shown converted to sus-
tained donor-derived hematopoiesis.
Figure 3. Kaplan-Meier probabilities of OS and DFS after CBT with
double unit grafts prepared with albumin-dextran dilution.
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are rapidly mixed with large volumes of isotonic solu-
tions or plasma. The osmotic damage inflicted by the
severe solute concentration gradient, however, can be
averted by a simple 2-fold dilution after thawing, pro-
viding almost total recovery of viable hematopoietic
progenitor cells’’ [1]. This suggests that the most im-
portant event in the thaw of cryopreserved CB may
be the initial dilution when the first osmotic shifts oc-
cur. We hypothesized that for larger CBT recipients
the centrifugation step may not therefore be necessary.
Dilution alone is an appealing simplification of the
thaw technique given that centrifugation can result in
cell loss, especially if the interface is not clear, and
can lead to increased unit manipulation especially if
clumping necessitates filtration of the product. Al-
though there may be concern that DMSO could be
toxic to the hematopoietic stem cells (HSC) [10] we
speculated that this could be mitigated by adequate
product dilution as well as prompt patient infusion.We also reasoned that clinical DMSO toxicity would
be tolerable because similar amounts of DMSO are
routinely administered to patients undergoing autolo-
gous transplantation [2]. Therefore, we investigated
a dilution-only strategy for the preparation of CB units
for infusion. A lower limit of 20 kg patient weight was
chosen for inclusion in this study given the risk of
DMSO infusion may be higher in smaller patients,
and these patients may not tolerate the large volumes
of the diluted products. Furthermore, young children
usually have higher cell dose products, and the poten-
tial cell loss that may occur with a wash may be
acceptable.
We found that the amount of DMSO estimated to
have been infused with the double-unit grafts (range:
0.05-0.28 g/kg of recipient weight) compared favor-
ably to that infused with autologous products [2]. Fur-
ther, infusion of unwashed CB was relatively well
tolerated even with the use of double-unit grafts. It
has previously been reported that 14 of 23 (61%) recip-
ients of washed double-unit grafts had no symptoms
associated with infusion [7]. Although this incidence
appears lower than that of infusion reactions we ob-
served with the ‘‘no-wash’’ dilution, a larger study
comparing the 2 techniques with uniform criteria for
defining a reaction would be required to truly reflect
the differences between these strategies. Further, we
found that the infusion reactions were safely managed
with the appropriate supportive care. Importantly,
units were infused with close nursing and medical su-
pervision, which is mandatory in the care of patients
receiving these products. Premedication and prompt
administration of additional medications to treat nau-
sea, hypertension, or other reactions during the infu-
sion is needed to ensure the safety of this approach as
well as patient comfort. In addition, although only 2
patients in the group of 54 had renal insufficiency after
the infusion, clinicians should be aware of the potential
for nephrotoxicity of the unwashed grafts, which is
Biol Blood Marrow Transplant 15:1596-1602, 2009 1601A ‘‘No-wash’’ Albumin-Dextran Dilution Strategy for Cord Blood Unit Thawpresumably from free hemoglobin and cellular debris.
We recommend hydration with crystalloids at a mini-
mum of 2 mL/kg/hour 6 hours pre-CBT and a mini-
mum of 24 hours after completion of the infusion. If
a rise in creatinine is observed, aggressive hydration
should be continued.
Whether our ‘‘no-wash’’ technique is an accept-
able alternative for units that are not RBC depleted
is difficult to determine based on only 3 units. It is
notable that all 3 recipients of RBC-replete units re-
acted to infusion including 1 patient with a significant
rise in creatinine to 2.7 mg/dL. Dilution of these
units may be more appealing than a bedside thaw
given that it is performed in the controlled laboratory
environment. Moreover, avoiding centrifugation may
also be an advantage, because washing of RBC-
replete units is associated with inferior engraftment
[11]. However, as the ‘‘no-wash’’ method does not
remove RBC debris and free hemoglobin, hydration
and close monitoring with infusion of these units is
extremely important, and the study of a larger num-
ber of patients is needed before it could be concluded
that the ‘‘no-wash’’ method of preparation for RBC
replete units is safe.
In addition to the tolerable infusion reaction pro-
file, a high rate of sustained donor engraftment was
observed in this study. This is likely contributed to
by all patients having hematologic malignancies
(reducing the risk of rejection compared to the trans-
plantation of nonmalignant disorders), the use of
highly immunosuppressive preparative regimens, and
the use of double-unit grafts. However, the finding
of a 94% incidence of sustained donor engraftment
suggests that DMSO does not have substantial toxicity
to hematopoietic progenitors, at least as practiced with
our methodology. Therefore, hematopoietic DMSO
toxicity cannot be used as an argument to substantiate
the practice of CB thaw with wash.
A further observation of this study was a lower rate
of aGVHD than that previously reported with double-
unit CBT in similar studies using washed products.
For example, incidences of 65% [7] and 59% [8] grade
II-IV aGVHD have been reported in similar studies of
MA and NMA CBT grafts, respectively. Although this
observation would require a controlled trial to con-
firm, one could postulate that the infusion of cells or
soluble factors usually removed in the washed product
could mediate an immunosuppressive effect and thus
possibly account for a modest reduction in the inci-
dence of aGVHD.
Finally, compared to the traditional wash, albu-
min-dextran dilution offers a number of additional
advantages. The reduction in technician time may
translate to cost savings for the cytotherapy laboratory.
This is especially relevant given the additional time re-
quired for the preparation of double-unit grafts for in-
fusion. Further, this technique may assist in a moreaccurate evaluation of unit quality. We perform
a flow cytometric assay to determine the viability of
the CD341 cells in the thawed product using 7-
amino-actinomycin D staining [12]. By evaluating
the unit without wash no dead cells are removed.
Therefore, on the day of transplant we can ascertain
the true percentage of live, viable cells in the thawed
units of the those originally present, and, therefore, en-
sure that a graft containing at least 1 unit with a high
percentage of viable cells and thus adequate quality
has been transplanted [12].
In summary, the albumin-dextran dilution of CB
units is associated with a tolerable infusion reaction
profile, a high rate of engraftment, and minimal
manipulation of the unit in the laboratory. It may
therefore be the method of choice for CBT in adults
and larger children .20 kg.ACKNOWLEDGMENTS
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